A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9651 participants.
Also called NCT03914326
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 9,651 participants
- Sponsor
- Registry
-
NCT03914326 -
2018-003141-42
-
- Other papers using this trial's data
- Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
- Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial
- Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czechia, Denmark, France, Germany, Hong Kong SAR China, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03914326. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2024-08-23 (actual). Results posted on 2025-09-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- Acronym
- SOUL
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03914326- Content hash
15d016496adbee58826826543b8e9c75aff8ca6239423e68e455f6cfa2ae92af